[Surrogate end points as a clinical and public health problem. The cerivastatin case].
Gérvas
Juan
J
Médico general, Canencia de la Sierra, Madrid, Spain. jgervasc@meditex.es
Pérez Fernández
Mercedes
M
D015415:Biomarkers; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D012306:Risk; D016896:Treatment Outcome
D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; C086276:cerivastatin